Publishing

CausalInferenceLab · Oct 30, 2024 · 5cd1bf0 · 5cd1bf0
1 parent 1ed1df5
commit 5cd1bf0
Show file tree

Hide file tree

Showing 2 changed files with 14 additions and 12 deletions.
diff --git a/_sources/docs/Framework_for_FDAs_RWE_Program_2.md b/_sources/docs/Framework_for_FDAs_RWE_Program_2.md
@@ -62,12 +62,13 @@
   - 연구 설계 및 분석의 투명성 확보가 결과에 대한 신뢰를 보장하는데 중요함
 
 ####  Regulatory Considerations for Study Designs Using RWD
-	- Use of Electronic Source Data
-  	- Electronic Source Data in Clinical Investigations (2013)
-    - Use of EHR in Clinical Investigations (2018)
-    - Use of Electronic Records and Electronic Signatures in Clinical Investigations under 21 CFR Q&A (2017)
-  - Regulatory Considerations for Clinical Studies generating RWE
-    - FDA는 RCT에서 생성된 데이터가 RWE 생성에 사용될 경우 어떻게 다룰 것인지도 평가 할 것
+
+- Use of Electronic Source Data
+  - Electronic Source Data in Clinical Investigations (2013)
+  - Use of EHR in Clinical Investigations (2018)
+  - Use of Electronic Records and Electronic Signatures in Clinical Investigations under 21 CFR Q&A (2017)
+- Regulatory Considerations for Clinical Studies generating RWE
+  - FDA는 RCT에서 생성된 데이터가 RWE 생성에 사용될 경우 어떻게 다룰 것인지도 평가 할 것
 
 #### Data Standards – Appropriate Data Standards for Integration and Submission to FDA
 - FDA는 RWD/RWE를 활용하기 위해 필요한 데이터 표준 및 구현 전략을 평가하고 FDA 규제의 필수적인 부분이 되도록 보장하기 위한 노력을 할 것

diff --git a/docs/Framework_for_FDAs_RWE_Program_2.html b/docs/Framework_for_FDAs_RWE_Program_2.html
@@ -506,13 +506,14 @@ <h3>Potential for Study Designs Using RWD to Support Effectiveness<a class="head
 </section>
 <section id="regulatory-considerations-for-study-designs-using-rwd">
 <h3>Regulatory Considerations for Study Designs Using RWD<a class="headerlink" href="#regulatory-considerations-for-study-designs-using-rwd" title="Permalink to this heading">#</a></h3>
-<div class="highlight-none notranslate"><div class="highlight"><pre><span></span>- Use of Electronic Source Data
-- Electronic Source Data in Clinical Investigations (2013)
-- Use of EHR in Clinical Investigations (2018)
-- Use of Electronic Records and Electronic Signatures in Clinical Investigations under 21 CFR Q&amp;A (2017)
-</pre></div>
-</div>
 <ul class="simple">
+<li><p>Use of Electronic Source Data</p>
+<ul>
+<li><p>Electronic Source Data in Clinical Investigations (2013)</p></li>
+<li><p>Use of EHR in Clinical Investigations (2018)</p></li>
+<li><p>Use of Electronic Records and Electronic Signatures in Clinical Investigations under 21 CFR Q&amp;A (2017)</p></li>
+</ul>
+</li>
 <li><p>Regulatory Considerations for Clinical Studies generating RWE</p>
 <ul>
 <li><p>FDA는 RCT에서 생성된 데이터가 RWE 생성에 사용될 경우 어떻게 다룰 것인지도 평가 할 것</p></li>